thought call
tripl combin progress advanc vertex well ahead competit
view notabl updat progress tripl combo program plan
move phase await detail trial name durat
primari endpoint believ progress could limit opportun
competitor galapago proteostasi cover allow vertex
maintain signific leadership posit speak compani tripl
tez/iva like begin therapi commenc
note data phase program strong het-min
patient treat combo demonstr increas
lung function materi safeti risk see thought addit
phase tripl data timelin nuanc program
materi concern us would like addit detail trial especi
regard safeti endpoint oper result solid set
continu growth formal cf revenu guidanc provid
pend approv tez/iva pdufa believ strong revenu growth
like continu launch tez/iva continu reimburs
decis ou strong oper result increas confid tripl
combo program increas pt maintain ow
pipelin beyond cf vertex provid updat earlier program name
collabor crispr cover smid biotech analyst gena wang
clinic trial expect begin beta-th europ sickl cell
diseas recal therapi use ex-vivo crispr technolog repres
earli trial sick patient success may help diversifi away cf
adjust estim base result fine-tun forecast
maintain cf revenu also
adjust opex howev result non-gaap ep estim
increas vs prior
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight anticip near-term growth
kalydeco follow fda decis includ
residu function mutat bolster
potenti approv tez iva later year
us eu overal top-lin growth larg
depend upon develop success tripl
combin phase data posit phase
set start mid
faster expect uptak orkambi ou
favor price persist complianc trend
continu expans kalydeco newli
indic cf popul robust uptak teza iva
global rapid develop tripl
combin set start phase
stagnat ou orkambi neg
discuss regul delay launch
reduc price development delay stumbl
tripl combo rapid develop emerg
compet product approach gene-
chang model
base result recent trend updat product forecast
oper expens outlook notabl kalydeco orkambi tezacaftor/ ivacaftor sale
forecast remain constant expens
also modestli declin cog
combin sg expens cog
declin combin sg increas slightli
result non-gaap ep increas
detail see figur
barclay research million except per share data
valuat pt base sum-of-th part npv analysi forecast
sale patent expir addit year potenti hatch-waxman extens
assum termin valu orkambi kalydeco tez iva tripl combo risk
adjust use discount rate forecast period
appropri reflect risk portfolio given assumpt assign valu
kalydeco orkambi tez iva tripl
combin pipelin valu net cash result total npv
previous pt base sum-of-th part npv analysi includ
risk adjust tripl combin rate discount rate forecast
period given assumpt assign valu kalydeco
orkambi tez iva tripl combin pipelin valu
net cash result total npv
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
